| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000015632 |
| Receipt No. | R000018093 |
| Official scientific title of the study | Neo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcer |
| Date of disclosure of the study information | 2014/11/07 |
| Last modified on | 2017/02/15 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Neo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcer | |
| Title of the study (Brief title) | NAC DS | |
| Region |
|
|
| Condition | ||
| Condition | gastric cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Safety of the neo adjubant chemotherapy by Docetaxel plus Tgafur-Gimeracil-Oteracil for gastric cancer |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | feasibility |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Neo adjuvant chemotherapy | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. adenocarcinoma
2. radical operation is possible by protcol operation 3. Stage IIB, IIIA, IIIB, IIIC patients except for distant metastasis 4. 20 < age <75 5. No preoperative treatment, such as radiotherapy, chemotherapy and hormone therapy 6. ingestionable patient 7. PS 0-1 8. without seriou complication 9. patient with consent |
|||
| Key exclusion criteria | 1. Active double cancer.
2. Administration contraindication of TS-1 3. Continuous use of flucytosine, phenytoin or warfarin potassium 4. History of severe drug allergy (over grade 3) 5. Severe complications 6. infection or acute infectious disease 7. HBV or HCV positive 8. Severe watery diarrhea 9. Female who are pregnant, nursing, suspected of being pregnant or hope to become pregnant during the study period. 10. No birth-control 11. Psychosis or Psychiatric disorder 12. Sever edema to treat 13. History of severe peripheral nerve disorder (over grade 2) 14. HIV positive 15. Patients judged inappropriate for the study by their physicians |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Hisahiro Matsubara |
| Organization | Graduate school of Medicine, Chiba University |
| Division name | Frontier Surgery |
| Address | 1-8-1, Inohan, Chuo-ku, Chiba |
| TEL | 043-226-2110 |
| naohana718@faculty.chiba-u.jp | |
| Public contact | |
| Name of contact person | Naoyuki Hanari |
| Organization | Graduate school of Medicine, Chiba University |
| Division name | Frontier Surgery |
| Address | 1-8-1, Inohan, Chuo-ku, Chiba |
| TEL | 043-226-2110 |
| Homepage URL | |
| naohana718@faculty.chiba-u.jp | |
| Sponsor | |
| Institute | Department of Frontier Surgery, Graduate school of Medicine, Chiba University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Frontier Surgery, Graduate school of Medicine, Chiba University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000018093 |